Comparative Pharmacology
Head-to-head clinical analysis: BRETYLOL versus SOTALOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETYLOL versus SOTALOL HYDROCHLORIDE.
BRETYLOL vs SOTALOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bretylium tosylate is an adrenergic neuron blocking agent that inhibits norepinephrine release and enhances its reuptake, resulting in postganglionic sympathetic blockade. It also has direct antiarrhythmic effects by increasing the ventricular fibrillation threshold.
Sotalol is a non-selective beta-adrenergic receptor antagonist (beta-blocker) with additional class III antiarrhythmic activity (prolongation of cardiac action potential duration via blockade of potassium channels). It decreases heart rate, myocardial contractility, and AV conduction velocity, and increases ventricular refractoriness.
Intravenous: 5-10 mg/kg over 10 minutes, then 5-10 mg/kg every 6-8 hours as needed for arrhythmias. Intramuscular: 5-10 mg/kg, may repeat every 6-8 hours.
Initial: 80 mg orally twice daily; may increase every 3 days to 160-320 mg/day, maximum 640 mg/day (for life-threatening arrhythmias). Also available as 80 mg intravenous over 20 minutes (1.5 mg/kg) for acute management.
None Documented
None Documented
Terminal elimination half-life is 7-11 hours in normal renal function; prolonged in renal impairment (up to 30 hours)
Terminal elimination half-life: 10-20 hours in normal renal function; prolonged in renal impairment (up to 40 hours), requiring dose adjustment.
Primarily renal excretion of unchanged drug (80-90%); minor biliary/fecal elimination (10-20%)
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <20%.
Category C
Category A/B
Antiarrhythmic (Class III)
Antiarrhythmic (Class III)